Abstract
Introduction: Immune checkpoint inhibitor‐related pancreatitis, also known as type 3 autoimmune pancreatitis (AIP), is uncommon and has a widely ranging clinical presentation. We present the biopsy findings of a case consistent with type 3 AIP—an entity recently described in the literature, the pathologic findings of which have not been well characterized. Case Report: A 71‐year‐old male with metastatic mucosal melanoma of the urethra was treated with immune checkpoint inhibitor (ICI) therapy (nivolumab/relatlimab) and developed vague epigastric discomfort. He was found to have an elevated lipase, which increased to > 20x the upper limit of normal. Subsequent imaging showed new infiltrative masses in the pancreatic head and distal body/tail. Endoscopic ultrasound with fine needle biopsy (FNB) was performed. This showed T‐lymphocyte predominant infiltrates, in the acini and septal areas, with concomitant acinar, duct, and venular damage, including both CD4 and CD8 lymphocytes, which were considered consistent with type 3 AIP. He was treated successfully with prednisone. Discussion: On biopsy, there was no evidence of malignancy or features of type 1 or type 2 AIP. Histologic findings included moderate infiltration and damage to the pancreatic parenchyma, ductal, and vascular structures by CD4 and CD8 lymphocytes, pointing to immune‐mediated pancreatic injury, and supportive of ICI‐mediated injury to the pancreas of this patient. The clinical presentation of type 3 AIP ranges from asymptomatic lipase elevation to asymptomatic pancreatitis to acute symptomatic pancreatitis. There may be no clear temporal relationship to treatment initiation. Type 3 AIP typically presents along with other immune‐related adverse events. Endoscopic ultrasound with FNB contributed to diagnostic certainty in this case and changed our patient’s management, allowing for appropriate treatment of his immune‐related adverse event.

This publication has 33 references indexed in Scilit: